Pfizer and Blackstone Life Sciences sign a co-funding deal in which Blackstone is set to provide up to $1.5 billion through 2028 to advance berobenatide.
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter ...
With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.
FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention. FDA has granted ...
Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering. argenx signed a ...
Zoe Lazarre, Claudia Ciciliano, and Shankar Narayanan assess where artificial intelligence (AI) is already proving its value ...
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward ...
Experts consider what happens when artificial intelligence (A) tools multiply faster than organizations can connect them.
A group of experts explore the advantages of purpose-built artificial intelligence (AI) for healthcare over generic models.
FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new ...
AstraZeneca has entered a deal to acquire Omniose, following a three-year exclusive research collaboration between the two organizations that both sides described as productive. C ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results